达雷妥尤单抗、来那度胺和地塞米松一线治疗POEMS综合征患者：一例报告
First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report.
作者信息
Amabile E, Fazio F, Martelli M, Petrucci M T
机构信息
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Azienda Policlinico Umberto I, Rome, Italy.
出版信息
Leuk Res Rep. 2024 Nov 26;22:100491. doi: 10.1016/j.lrr.2024.100491. eCollection 2024.
Abstract
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome) is a rare condition due to an underlying plasma cell neoplasm whose clinical presentation can be various so it could lead to delayed diagnosis and treatment. The pathogenesis of the syndrome is not well understood, and its therapy is adapted from other plasma cell disorders with the aim of alleviating symptoms, decreasing end-organ damage, improving quality of life and prolonging overall survival. We report a case of a 71 years-old woman who has been treated with continuous DRd (daratumumab, lenalidomide and dexamethasone) scheme.
摘要
POEMS综合征（多发性神经病、脏器肿大、内分泌病、M蛋白、皮肤改变综合征）是一种由潜在浆细胞肿瘤引起的罕见病症，其临床表现多样，可能导致诊断和治疗延迟。该综合征的发病机制尚不完全清楚，其治疗方法借鉴了其他浆细胞疾病，目的是缓解症状、减少终末器官损害、提高生活质量并延长总生存期。我们报告一例71岁女性患者，该患者接受了持续DRd（达雷妥尤单抗、来那度胺和地塞米松）方案治疗。
相似文献
1
First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report.达雷妥尤单抗、来那度胺和地塞米松一线治疗POEMS综合征患者：一例报告
Leuk Res Rep. 2024 Nov 26;22:100491. doi: 10.1016/j.lrr.2024.100491. eCollection 2024.
2
Essential thrombocythemia as an initial presentation of polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome with complete response to the bortezomib, cyclophosphamide, dexamethasone regimen: a case report.原发性血小板增多症作为多神经病、器官肿大、内分泌病、M蛋白、皮肤改变综合征的初始表现，对硼替佐米、环磷酰胺、地塞米松方案完全缓解：一例报告
J Med Case Rep. 2025 Jul 1;19(1):301. doi: 10.1186/s13256-025-05338-4.
3
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.POEMS（多发性神经病变、器官肿大、内分泌病、M蛋白和皮肤改变）综合征的治疗。
Cochrane Database Syst Rev. 2008 Oct 8(4):CD006828. doi: 10.1002/14651858.CD006828.pub2.
4
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.POEMS（多发性神经病变、器官肿大、内分泌病、M蛋白和皮肤改变）综合征的治疗。
Cochrane Database Syst Rev. 2012 Jun 13;2012(6):CD006828. doi: 10.1002/14651858.CD006828.pub3.
5
Successful treatment with carfilzomib and dexamethasone for relapsed/refractory POEMS syndrome: a case report and review of literature.卡非佐米和地塞米松成功治疗复发/难治性POEMS综合征：一例报告及文献复习
Front Oncol. 2025 Jun 6;15:1570981. doi: 10.3389/fonc.2025.1570981. eCollection 2025.
6
Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.采用达雷妥尤单抗、来那度胺和地塞米松联合治疗，随后进行自体造血干细胞移植治疗新诊断的多发性神经病、器官肿大、内分泌病、M 蛋白、皮肤改变综合征：一例报告。
J Med Case Rep. 2022 Aug 18;16(1):311. doi: 10.1186/s13256-022-03552-y.
7
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
8
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理（2025年结石病专家共识）
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
9
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益：一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.
10
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
本文引用的文献
1
POEMS syndrome: Update on diagnosis, risk-stratification, and management.POEMS综合征：诊断、风险分层及管理的最新进展
Am J Hematol. 2023 Dec;98(12):1934-1950. doi: 10.1002/ajh.27081. Epub 2023 Sep 21.
2
Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.采用达雷妥尤单抗、来那度胺和地塞米松联合治疗，随后进行自体造血干细胞移植治疗新诊断的多发性神经病、器官肿大、内分泌病、M 蛋白、皮肤改变综合征：一例报告。
J Med Case Rep. 2022 Aug 18;16(1):311. doi: 10.1186/s13256-022-03552-y.
3
POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis.POEMS综合征：诊断与全身治疗的真实世界经验——108例患者的多中心分析
Clin Lymphoma Myeloma Leuk. 2022 May;22(5):297-304. doi: 10.1016/j.clml.2021.10.007. Epub 2021 Oct 31.
4
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.达雷妥尤单抗、来那度胺和地塞米松与来那度胺和地塞米松单独治疗新诊断多发性骨髓瘤（MAIA）的疗效比较：一项随机、开放标签、3 期临床试验的总生存结果。
Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13.
5
Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- A Systematic Review.
Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):e26-e33. doi: 10.1016/j.clml.2021.07.033. Epub 2021 Aug 2.
6
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome.达雷妥尤单抗联合来那度胺和地塞米松一线治疗POEMS综合征
Hemasphere. 2020 May 21;4(3):e381. doi: 10.1097/HS9.0000000000000381. eCollection 2020 Jun.
7
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗新诊断多发性骨髓瘤（ALCYONE）的总生存：一项随机、开放标签、3 期临床试验。
Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.
Zotero 插件